Rapid Communication
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jul 7, 2008; 14(25): 4059-4064
Published online Jul 7, 2008. doi: 10.3748/wjg.14.4059
Table 1 Stage classification of gastric ulcer by Sakita-Miwa and its translation into numerical expression[26]
StagesManifestation
Active stageA1 (6p)The surrounding mucosa is edematously swollen and no regenerating epithelium is seen endoscopically
A2 (5p)The surrounding edema has decreased, the ulcer margin is clear, and a slight amount of regenerating epithelium is seen in the ulcer margin. A red halo in the marginal zone and a white slough circle in the ulcer margin are frequently seen. Usually, converging mucosal folds can be followed right up to the ulcer margin
Healing stageH1 (4p)The white coating is becoming thin and the regenerating epithelium is extending into the ulcer base. The gradient between the ulcer margin and the ulcer floor is becoming flat. The ulcer crater is still evident and the margin of the ulcer is sharp. The diameter of the mucosal defect is about one-half to two-thirds that of A1
H2 (3p)The defect is smaller than in H1 and the regenerating epithelium covers most of the ulcer floor. The area of white coating is about a quarter to one-third that of A1
Scarring stageS1 (2p)The regenerating epithelium completely covers the floor of ulcer. The white coating has disappeared. Initially, the regenerating region is markedly red. Upon close observation, many capillaries can be seen. This is called “red scar”
S2 (1p)In several months to a few years, the redness is reduced to the color of the surrounding mucosa. This is called “white scar”
Table 2 Clinical features of the ischemic colitis patients: Comparison between the rebamipide and conventional therapy groups
Conventional group (n = 9)Rebamipide group (n = 6)Statistical significance
Age (mean, range, yr)68 ± 19 (35-87)69 ± 16 (41-85)NS
Percentage of females (%)77.866.7NS
Lesion location: left colon (%)88.9100NS
Performance status 0-1 (%)77.8100NS
WBC count (× 103/&mgr;L)12.3 ± 4.713.5 ± 5.3NS
CRP (mg/dL)2.6 ± 4.11.7 ± 1.8NS
K (mEq/L)3.8 ± 0.44.2 ± 0.5NS
Total cholesterol (mg/dL)179.3 ± 30.6191.2 ± 63.0NS
TG (mg/dL)93.3 ± 41.0131.2 ± 74.2NS
LDH (IU/L)190.0 ± 42.8202.8 ± 18.2NS
CPK (IU/L)80.7 ± 38.9118.0 ± 76.6NS
Table 3 Underlying disease: Comparison between the rebamipide and conventional therapy groups n (%)
Conventional group (n = 9)Rebamipide group (n = 6)Statistical significance
Hypertension6 (66.7)2 (33.3)NS
Hyperlipidemia03 (50.0)NS
Diabetes mellitus1 (11.1)1 (16.7)NS
Atrial fibrillation1 (11.1)0NS
Cerebral infarction1 (11.1)0NS
Chronic constipation5 (55.6)1 (16.7)NS
Medications
Antihypertensive agents5 (55.6)1 (16.7)NS
Others1 (11.1)1 (16.7)NS
History of abdominal surgery4 (44.4)3 (50.0)NS
Table 4 Duration of fasting, duration of hospitalization and reduction in the ulcer score: Comparison between the rebamipide and conventional therapy groups
Conventional group (n = 9)Rebamipide group (n = 6)Statistical significance
Duration of fasting (d)7.9 ± 4.12.7 ± 1.8P = 0.0121
Duration of hospitalization (d)17.9 ± 6.89.2 ± 1.5P = 0.0092
Degree of ulcer healing1 (points)2.8 ± 0.5 (n = 5)3.5 ± 0.5P = 0.0797
WBC decrease2 (× 103/&mgr;L)8.6 ± 5.712.0 ± 5.6P = 0.3360